Zhanglong Chen - Sinphar Pharmaceutical Chief Marketing Center Officer
| 1734 Stock | TWD 37.00 0.05 0.14% |
Executive
Zhanglong Chen is Chief Marketing Center Officer of Sinphar Pharmaceutical Co since 2008.
| Tenure | 16 years |
| Phone | 886 0 3958 1101 |
| Web | https://www.sinphar.com.tw |
Sinphar Pharmaceutical Management Efficiency
The company has return on total asset (ROA) of 0.0207 % which means that it generated a profit of $0.0207 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0444 %, meaning that it generated $0.0444 on every $100 dollars invested by stockholders. Sinphar Pharmaceutical's management efficiency ratios could be used to measure how well Sinphar Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 5 records | EXECUTIVE Age | ||
| Xinhui Lin | Abnova Taiwan Corp | N/A | |
| Hanwen Guan | Abnova Taiwan Corp | N/A | |
| Yinshou Lin | Phytohealth Corp | N/A | |
| Yihuang Huang | Abnova Taiwan Corp | N/A | |
| Menghong Chen | Abnova Taiwan Corp | N/A | |
Management Performance
| Return On Equity | 0.0444 | |||
| Return On Asset | 0.0207 |
Sinphar Pharmaceutical Leadership Team
Elected by the shareholders, the Sinphar Pharmaceutical's board of directors comprises two types of representatives: Sinphar Pharmaceutical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sinphar. The board's role is to monitor Sinphar Pharmaceutical's management team and ensure that shareholders' interests are well served. Sinphar Pharmaceutical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sinphar Pharmaceutical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| YiMei Lou, Finance Director, IR Contact Officer | ||
| Lingmo Zhao, Director | ||
| Nengying You, General Manager-China Affair Office | ||
| NenYing You, General Manager-Mainland China Affair Office | ||
| Lirong Xie, Head-Accounting, Deputy Manager | ||
| Yunze Lu, General Manager-I-LAN Factory Service Office | ||
| YuLiang Pai, General Manager | ||
| Fengqin Zhang, Deputy General Manager-Marketing Center | ||
| Hanqin Lin, Deputy Chief Research & Development Officer | ||
| Xiumin Lin, Director | ||
| Yida Li, Chief Research and Development Officer, Director | ||
| Xiuji Guo, Director | ||
| ChihWen Lee, Chairman of the Board | ||
| Boxiong Lai, Director | ||
| Jinlong Li, Director | ||
| ChinLung Lee, Independent Director | ||
| Zhanglong Chen, Chief Marketing Center Officer | ||
| NenYu You, General Manager-Subsidiary | ||
| ChihHsiao Chen, Head of Finance | ||
| Zhiwen Li, Chairman of the Board | ||
| Li Xie, Accounting Head | ||
| ChaoRe Wang, General Manager-Subsidiary | ||
| JingJing Tang, Deputy Chief Research & Development Officer | ||
| Youlang Bai, General Manager | ||
| YiTa Lee, Chief Research & Development Officer, Director | ||
| Yaoyuan Wen, Independent Director |
Sinphar Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Sinphar Pharmaceutical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0444 | |||
| Return On Asset | 0.0207 | |||
| Profit Margin | 0.07 % | |||
| Operating Margin | 0.07 % | |||
| Current Valuation | 6.26 B | |||
| Shares Outstanding | 167.72 M | |||
| Shares Owned By Insiders | 20.27 % | |||
| Shares Owned By Institutions | 1.49 % | |||
| Price To Earning | 536.84 X | |||
| Price To Book | 1.88 X |
Thematic Opportunities
Explore Investment Opportunities
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Sinphar Pharmaceutical Co. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Complementary Tools for Sinphar Stock analysis
When running Sinphar Pharmaceutical's price analysis, check to measure Sinphar Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sinphar Pharmaceutical is operating at the current time. Most of Sinphar Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Sinphar Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sinphar Pharmaceutical's price. Additionally, you may evaluate how the addition of Sinphar Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
| CEOs Directory Screen CEOs from public companies around the world | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes |